Filing Flows › Quest Diagnostics (DGX) › Q3 2026
Quest Diagnostics (DGX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 23, 2026
Quest Diagnostics (DGX) reported revenue of $3.1B for the third quarter 2026 (Q3 2026), +10% from a year earlier and +2% from the quarter before. Operating margin was 15.5%, net earnings $312M (10.1% of revenue).
Quest Diagnostics, Q3 2026: revenue $3.1B (+10% year over year), operating margin 15.5%, net earnings $312M, operating cash flow $611M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.1B | +2% | +10% |
| Operating profit | $479M | +4% | +24% |
| Net earnings | $312M | -3% | +27% |
| Operating cash flow | $611M | +2% | +9% |
| Free cash flow | $445M | -3% | +6% |
What changed
Revenue was $3.1B in Q3 2026, up 10% year over year and up 2% from the previous quarter. DIS business was the largest line at 98% of revenue. DIS business added $0.28B year over year (up 10%), 100% of the total change.
Operating profit was $0.48B, a 15.5% margin (up 1.8 points year over year). Of the extra revenue versus Q3 2025, 33% reached operating profit, above the 14% margin then. Total costs grew 8% against revenue growth of 10%. The fastest-growing cost line was Cost of revenue (+10%). Net earnings were $0.31B, up 27% year over year. The effective tax rate was 23.3%.
Operating cash flow was $0.61B (up 9% year over year), 187% of net income including minority interests. Non-cash charges added back $0.15B of depreciation and amortization and $0.02B of share-based compensation. Working capital and other items added $0.12B. Capital expenditures of $0.17B left free cash flow of $0.45B.
Questions
What was Quest Diagnostics' revenue in the third quarter 2026?
Quest Diagnostics (DGX) reported revenue of $3.1B for the third quarter 2026 (Q3 2026), +10% from a year earlier and +2% from the quarter before.
Was Quest Diagnostics profitable in the third quarter 2026?
Operating profit was $479M (15.5% of revenue) and net earnings $312M.
Source: Quest Diagnostics 10-Q on SEC EDGAR.